Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA24477V1058
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00F13HYQ7
DFTX
Definium Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology
NAME
Definium Therapeutics, Inc.
ISIN
CA24477V1058
TICKER
DFTX
MIC
XNAS
REUTERS
MNMD.OQ
BLOOMBERG
MNMD US
Mi., 24.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without pa...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its c...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 21.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its f...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of optio...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healt...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluati...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 11.05.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options t...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights. “After...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.04.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May 7, 2026 to report financial results for the first...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and comme...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options t...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, d...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live questi...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) optio...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported its full-year 2025 financial results and provided business updates. “We are proud of the strong exec...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 24.02.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the follo...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26,...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-exec...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. “We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep exp...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Definium Therapeutics
CA24477V1058

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-ex...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Definium Therapeutics
CA24477V1058

Das Instrument MMQ0 CA24477V1058 DEFINIUM THERAP.INC. O.N. EQUITY hat seinen ersten Handelstag am 21.01.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument MMQ0 CA24477V1058 DEFINIUM THERAP.INC. O.N. EQUITY has its first trading date on 21.01.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
Zur Nachricht
Definium Therapeutics
Charts & Research Termsheets Terminal
Permalink